Serial monitoring of N-terminal B-type natriuretic peptide (NT-proBNP) in patients with type 2 diabetes (T2D) and ischemic heart disease may be useful for identifying patients at highest risk for heart failure (HF), a recent study suggests. NT-proBNP was measured at baseline and 6 months. Cardiovascular (CV) death or hospitalization for HF was the primary end point. Researchers found:
- A graded relationship between increasing baseline and 6-month NT-proBNP concentration and the incidence of major CV events was observed.
- After adjusting for potential confounders, NT-proBNP at baseline was independently associated with the development of major CV events, especially hospitalization for HF.
- Patients with persistently high NT-proBNP or developed high NT-proBNP at 6 months were at a significantly higher risk for CV death/HF than those in whom NT-proBNP remained low at both time points.
- Treatment with a DPP-4 inhibitor did not meaningfully alter NT-proBNP concentrations.
Jarolim P, White WB, Cannon CP, Gao Q, Morrow DA. Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE Trial. [Published online ahead of print May 30, 2018]. Diabetes Care. doi:10.2337/dc18-0109.
This Week's Must Reads
Must Reads in Cardiology
Consumption of SSBs & Risk of Mortality, Circulation; ePub 2019 Mar 18; Malik, et al
Dietary Cholesterol or Egg Consumption & CVD, JAMA; 2019 Mar 19; Zhong, Van Horn, et al
Physical Activity & Incidence of CHD & CVD in Women, JAMA Netw Open; ePub 2019 Mar 15; LaCroix, et al